Immunic showcases MS drug data at BIO International Convention in Boston - ICYMI

  • Immunic Inc (NASDAQ:IMUX) chief operating officer Jason Tardio talked with Proactive about the company's participation at the BIO International Convention in Boston and recent clinical developments. Tardio highlighted Immunic's ongoing business development efforts, particularly around its lead asset, vidofludimus calcium, aimed at treating multiple sclerosis (MS).